Savill Corrine 4
4 · Cullinan Oncology, Inc. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Savill Corrine
Chief Business Officer
Transactions
- Sale
Common Stock
2024-02-01$16.18/sh−40,000$647,200→ 165,990 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-01−40,000→ 70,331 totalExercise: $4.30Exp: 2030-10-31→ Common Stock (40,000 underlying) - Exercise/Conversion
Common Stock
2024-02-01$4.30/sh+40,000$172,000→ 205,990 total
Footnotes (3)
- [F1]Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.52. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]25% of the shares vested on September 1, 2019, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on September 1, 2022.